Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026

Eli Lilly's stock is predicted to reach $1,400 by end of 2026 (15% gain from July levels), driven by expanded drug access rather than efficacy. The company's new oral obesity drug Foundayo, combined with $27 billion in manufacturing expansion, direct pharmacy distribution, and Medicare pricing deals, positions it to reach patients that injectable competitors cannot. However, competition from Novo Nordisk, premium valuation, and execution risks remain concerns.